Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
ACS Medicinal Chemistry Letters
|
February 18, 2026
Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series
Giovanni Ferrandi, Greta Bagnolini, Laura Poppi, et al.
Angewandte Chemie (International Ed. in English)
|
November 4, 2023
Isolation and Characterization of Monomeric Human RAD51: A Novel Tool for Investigating Homologous Recombination in Cancer
Francesco Rinaldi, Fabrizio Schipani, Beatrice Balboni, et al.
European Journal of Medicinal Chemistry
|
December 27, 2021
ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders
Stefania Demuro, Conall Sauvey, Shailesh K Tripathi, et al.
ACS Medicinal Chemistry Letters
|
August 18, 2022
Identification of RAD51-BRCA2 Inhibitors Using <i>N</i>-Acylhydrazone-Based Dynamic Combinatorial Chemistry
Greta Bagnolini, Beatrice Balboni, Fabrizio Schipani, et al.
Nature Communications
|
December 1, 2025
Computationally-designed aptamers targeting RAD51-BRCA2 interaction impair homologous recombination and induce synthetic lethality
Giulia Milordini, Elsa Zacco, Mirco Masi, et al.
Journal of Medicinal Chemistry
|
April 7, 2023
Design, Synthesis, <i>In Vitro</i> and <i>In Vivo</i> Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer
Nicoletta Brindani, Linh M Vuong, Isabella Maria Acquistapace, et al.
Journal of Medicinal Chemistry
|
July 13, 2023
Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5
Irene Brusa, Elvira Sondo, Emanuela Pesce, et al.
European Journal of Medicinal Chemistry
|
January 21, 2019
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells
Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, et al.
European Journal of Medicinal Chemistry
|
January 9, 2024
An <sup>19</sup>F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer
Samuel H Myers, Laura Poppi, Francesco Rinaldi, et al.
Journal of Medicinal Chemistry
|
June 12, 2024
Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy
Nicoletta Brindani, Linh M Vuong, Maria Antonietta La Serra, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
ACS Medicinal Chemistry Letters
|
February 18, 2026
Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series
Giovanni Ferrandi, Greta Bagnolini, Laura Poppi, et al.
Angewandte Chemie (International Ed. in English)
|
November 4, 2023
Isolation and Characterization of Monomeric Human RAD51: A Novel Tool for Investigating Homologous Recombination in Cancer
Francesco Rinaldi, Fabrizio Schipani, Beatrice Balboni, et al.
European Journal of Medicinal Chemistry
|
December 27, 2021
ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders
Stefania Demuro, Conall Sauvey, Shailesh K Tripathi, et al.
ACS Medicinal Chemistry Letters
|
August 18, 2022
Identification of RAD51-BRCA2 Inhibitors Using <i>N</i>-Acylhydrazone-Based Dynamic Combinatorial Chemistry
Greta Bagnolini, Beatrice Balboni, Fabrizio Schipani, et al.
Nature Communications
|
December 1, 2025
Computationally-designed aptamers targeting RAD51-BRCA2 interaction impair homologous recombination and induce synthetic lethality
Giulia Milordini, Elsa Zacco, Mirco Masi, et al.
Journal of Medicinal Chemistry
|
April 7, 2023
Design, Synthesis, <i>In Vitro</i> and <i>In Vivo</i> Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer
Nicoletta Brindani, Linh M Vuong, Isabella Maria Acquistapace, et al.
Journal of Medicinal Chemistry
|
July 13, 2023
Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5
Irene Brusa, Elvira Sondo, Emanuela Pesce, et al.
European Journal of Medicinal Chemistry
|
January 21, 2019
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells
Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, et al.
European Journal of Medicinal Chemistry
|
January 9, 2024
An <sup>19</sup>F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer
Samuel H Myers, Laura Poppi, Francesco Rinaldi, et al.
Journal of Medicinal Chemistry
|
June 12, 2024
Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy
Nicoletta Brindani, Linh M Vuong, Maria Antonietta La Serra, et al.
Page
of 5